Pfizer Inc. $PFE Stake Cut by Commonwealth Retirement Investments LLC

Commonwealth Retirement Investments LLC reduced its holdings in Pfizer Inc. (NYSE:PFE) by 72.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,579 shares of the biopharmaceutical company’s stock after selling 19,707 shares during the period. Commonwealth Retirement Investments LLC’s holdings in Pfizer were worth $189,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Triad Wealth Partners LLC lifted its stake in Pfizer by 1.9% in the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after acquiring an additional 386 shares in the last quarter. ETF Store Inc. lifted its stake in Pfizer by 3.8% in the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after acquiring an additional 396 shares in the last quarter. Mattern Wealth Management LLC lifted its stake in Pfizer by 4.6% in the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock worth $228,000 after acquiring an additional 400 shares in the last quarter. Pines Wealth Management LLC lifted its stake in Pfizer by 4.4% in the 4th quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 400 shares in the last quarter. Finally, Pathway Financial Advisers LLC lifted its stake in Pfizer by 0.9% in the 4th quarter. Pathway Financial Advisers LLC now owns 46,380 shares of the biopharmaceutical company’s stock worth $1,155,000 after acquiring an additional 403 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of PFE stock opened at $25.66 on Tuesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75. The stock’s 50-day moving average is $26.59 and its two-hundred day moving average is $26.30. The firm has a market cap of $146.22 billion, a P/E ratio of 19.58 and a beta of 0.34.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same period in the prior year, the firm posted $0.92 EPS. The business’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. Pfizer’s dividend payout ratio is currently 131.30%.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Royal Bank Of Canada reissued an “underperform” rating and issued a $25.00 price objective on shares of Pfizer in a research note on Monday, April 20th. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a research report on Monday, March 2nd. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Pfizer in a research report on Monday, June 1st. Finally, CICC Research began coverage on Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.82.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported encouraging Phase 2b data for its once-monthly obesity drug, showing about 15.9% to 16% weight loss, reinforcing hopes that the company could become a more meaningful player in the fast-growing weight-loss market. Pfizer’s obesity drug shows 16% weight loss in phase 2b study
• Positive Sentiment: The U.S. FDA expanded approval of Pfizer’s HYMPAVZI for additional hemophilia A and B patient groups, including pediatric patients, which should widen the drug’s addressable market and support future sales growth. U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
• Positive Sentiment: Unusually heavy call-option activity suggests traders are positioning for more upside in PFE, reflecting rising near-term optimism around the company’s pipeline news.
• Neutral Sentiment: Pfizer also presented at Goldman Sachs’ Global Healthcare Conference, but no major new strategic update was highlighted in the available summary. Pfizer Inc. (PFE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Competition in obesity drugs remains intense, with another company reporting strong weight-loss results, reminding investors that Pfizer will need to keep delivering to compete in this high-profile market. Sciwind Reports 12.8% Weight Loss As Global Expansion Talks Deepen

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.